Transgene SA (TNG)
Euronext Paris · France · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 0.683 |
|---|---|
| 52-week range | 0.679 – 1.500 |
| Return, 1 month / 3 months | −20.6% / −6.1% |
| Return, 1 year / 3 years | −47.7% / −51.9% |
| Trend | Below its 200-day average |
| RSI (14) | 31 |
| Volatility (1 year) | 48.7% |
| Worst drawdown (1 year) | -53.8% |
| Average daily value traded | 0.09M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Transgene is a French biotechnology company based near Strasbourg that designs and develops immunotherapies for cancer. Its work centres on therapeutic vaccines and oncolytic viruses, engineered to help the immune system recognise and attack tumour cells. The company carries out laboratory research and clinical development of these product candidates, working with hospitals and research partners, and its programmes are aimed at treating solid tumours and other cancers.
Transgene SA trades under the code TNG on the Euronext Paris in France, with its price quoted in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Transgene SA (TNG) trades on the Euronext Paris in France. It last closed at EUR 0.683 on 19 October 2026.
Its price-based Market X-Ray is 41 out of 100 (a weak price profile), ranking 419 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 47.7% and over the last three months it fell 6.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 38 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -14.0% | ||
| From 52-week high | -53.7% | ||
| Momentum | 40 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -6.1% | ||
| 6-month return | -9.8% | ||
| 12-month return, skipping the last month | -34.1% | ||
| Stability (higher is calmer) | 33 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 48.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -53.8% | ||
| Liquidity | 63 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.09M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −1.9% |
|---|---|
| 1 month | −20.6% |
| 3 months | −6.1% |
| 6 months | −9.8% |
| 1 year | −47.7% |
| 3 years | −51.9% |
| 5 years | −71.4% |
Signals
| 50-day / 200-day average | 0.782 / 0.794 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.020 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.